Morgan Stanley projects about a third of biotechs will need financing in 2022
Morgan Stanley says about a third of biotechs will need financing in 2022 (NASDAQ:EDIT)
Mar 26, 2022 by Seeking Alpha
- RL Photography/iStock via Getty Images About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms.
- While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the overall cash needs at approximately $36 billion are higher, the analysts added.
- Notably, the 110 companies with potential funding needs have performed slightly lower than the industry average in the recent past, the analysts added, pointing to an average return of -39% over the past six months compared to the -33% decline in the SPDR S&P Biotech ETF (NYSEARCA:XBI).
- However, the analysts acknowledged that the projection might have excluded some of the companies that had major milestones in 2021, which are unlikely to repeat in 2022.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to firstname.lastname@example.org. © 2021 Kwhen Inc.
Was this content valuable for you?